Supplementary material from Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Autor: Amit M. Oza, Tony W. Ho, J. Carl Barrett, Jonathan Ledermann, Jane D. Robertson, Mark J. O'Connor, C. Blake Gilks, Julia V. Burnier, Katherine Karakasis, Tony Panzarella, Ursula Matulonis, Claire Scott, Elise C. Kohn, David Bowtell, Charlie Gourley, Stan Kaye, Jerry S. Lanchbury, Kirsten M. Timms, Darren R. Hodgson, Sarah Runswick, Brian A. Dougherty, Zhongwu Lai, Stephanie Lheureux
Rok vydání: 2023
DOI: 10.1158/1078-0432.22468700.v1
Popis: Supplementary Figure 1. Mutational analysis of TP53 in the olaparib arm. (A) Analysis of TP53 mutation type. (B) BRCA1 and BRCA2 mutation type Supplementary Table 1. Platinum sensitivity and outcome on olaparib maintenance treatment. Supplementary Table 2. Mutational analysis of the FoundationOne® panel from the LT and ST responders in the olaparib arm. Supplementary Table 3. Mutational analysis of PTEN in the olaparib and placebo arms. Supplementary Table 4. Analysis of BRCA1, BRCA2, and TP53 mutation frequency in olaparib patients in the LT and ST responder group.
Databáze: OpenAIRE